vs

Side-by-side financial comparison of ALAMO GROUP INC (ALG) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $373.6M, roughly 1.7× ALAMO GROUP INC). Royalty Pharma plc runs the higher net margin — 34.4% vs 4.2%, a 30.3% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -3.0%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -6.3%).

The Alamo Drafthouse Cinema is an American cinema chain founded in 1997 in Austin, Texas, which is famous for serving dinner and drinks during the film, as well as its strict policy of requiring its audiences to maintain proper cinema-going etiquette. Sony Pictures Experiences acquired the chain in June 2024.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

ALG vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.7× larger
RPRX
$622.0M
$373.6M
ALG
Growing faster (revenue YoY)
RPRX
RPRX
+7.8% gap
RPRX
4.8%
-3.0%
ALG
Higher net margin
RPRX
RPRX
30.3% more per $
RPRX
34.4%
4.2%
ALG
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-6.3%
ALG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALG
ALG
RPRX
RPRX
Revenue
$373.6M
$622.0M
Net Profit
$15.5M
$214.2M
Gross Margin
22.7%
Operating Margin
6.0%
62.4%
Net Margin
4.2%
34.4%
Revenue YoY
-3.0%
4.8%
Net Profit YoY
-44.8%
2.9%
EPS (diluted)
$1.28
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALG
ALG
RPRX
RPRX
Q4 25
$373.6M
$622.0M
Q3 25
$420.0M
$609.3M
Q2 25
$419.1M
$578.7M
Q1 25
$390.9M
$568.2M
Q4 24
$385.3M
$593.6M
Q3 24
$401.3M
$564.7M
Q2 24
$416.3M
$537.3M
Q1 24
$425.6M
$568.0M
Net Profit
ALG
ALG
RPRX
RPRX
Q4 25
$15.5M
$214.2M
Q3 25
$25.4M
$288.2M
Q2 25
$31.1M
$30.2M
Q1 25
$31.8M
$238.3M
Q4 24
$28.1M
$208.2M
Q3 24
$27.4M
$544.0M
Q2 24
$28.3M
$102.0M
Q1 24
$32.1M
$4.8M
Gross Margin
ALG
ALG
RPRX
RPRX
Q4 25
22.7%
Q3 25
24.2%
Q2 25
25.8%
Q1 25
26.3%
Q4 24
23.8%
Q3 24
25.1%
Q2 24
26.0%
Q1 24
26.2%
Operating Margin
ALG
ALG
RPRX
RPRX
Q4 25
6.0%
62.4%
Q3 25
8.9%
70.1%
Q2 25
11.2%
36.3%
Q1 25
11.4%
94.0%
Q4 24
8.9%
60.9%
Q3 24
10.0%
Q2 24
10.4%
50.2%
Q1 24
11.0%
-13.0%
Net Margin
ALG
ALG
RPRX
RPRX
Q4 25
4.2%
34.4%
Q3 25
6.0%
47.3%
Q2 25
7.4%
5.2%
Q1 25
8.1%
41.9%
Q4 24
7.3%
35.1%
Q3 24
6.8%
96.3%
Q2 24
6.8%
19.0%
Q1 24
7.5%
0.8%
EPS (diluted)
ALG
ALG
RPRX
RPRX
Q4 25
$1.28
$0.49
Q3 25
$2.10
$0.67
Q2 25
$2.57
$0.07
Q1 25
$2.64
$0.55
Q4 24
$2.33
$0.46
Q3 24
$2.28
$1.21
Q2 24
$2.35
$0.23
Q1 24
$2.67
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALG
ALG
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$309.7M
$618.7M
Total DebtLower is stronger
$190.7M
$9.0B
Stockholders' EquityBook value
$1.1B
$9.7B
Total Assets
$1.6B
$19.6B
Debt / EquityLower = less leverage
0.17×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALG
ALG
RPRX
RPRX
Q4 25
$309.7M
$618.7M
Q3 25
$244.8M
$938.9M
Q2 25
$201.8M
$631.9M
Q1 25
$200.3M
$1.1B
Q4 24
$197.3M
$929.0M
Q3 24
$140.0M
$950.1M
Q2 24
$118.5M
$1.8B
Q1 24
$121.8M
$843.0M
Total Debt
ALG
ALG
RPRX
RPRX
Q4 25
$190.7M
$9.0B
Q3 25
$194.4M
$8.9B
Q2 25
$198.1M
$8.0B
Q1 25
$201.8M
$7.6B
Q4 24
$205.5M
$7.6B
Q3 24
$209.2M
$7.6B
Q2 24
$278.6M
$7.6B
Q1 24
$306.5M
$6.1B
Stockholders' Equity
ALG
ALG
RPRX
RPRX
Q4 25
$1.1B
$9.7B
Q3 25
$1.1B
$9.6B
Q2 25
$1.1B
$9.5B
Q1 25
$1.1B
$9.8B
Q4 24
$1.0B
$10.3B
Q3 24
$1.0B
$10.3B
Q2 24
$979.7M
$9.8B
Q1 24
$956.6M
$9.9B
Total Assets
ALG
ALG
RPRX
RPRX
Q4 25
$1.6B
$19.6B
Q3 25
$1.6B
$19.3B
Q2 25
$1.6B
$18.3B
Q1 25
$1.5B
$17.6B
Q4 24
$1.5B
$18.2B
Q3 24
$1.5B
$18.0B
Q2 24
$1.5B
$17.7B
Q1 24
$1.5B
$16.1B
Debt / Equity
ALG
ALG
RPRX
RPRX
Q4 25
0.17×
0.92×
Q3 25
0.17×
0.93×
Q2 25
0.18×
0.84×
Q1 25
0.19×
0.78×
Q4 24
0.20×
0.74×
Q3 24
0.21×
0.74×
Q2 24
0.28×
0.78×
Q1 24
0.32×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALG
ALG
RPRX
RPRX
Operating Cash FlowLast quarter
$75.1M
$827.1M
Free Cash FlowOCF − Capex
$69.9M
FCF MarginFCF / Revenue
18.7%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
4.84×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$146.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALG
ALG
RPRX
RPRX
Q4 25
$75.1M
$827.1M
Q3 25
$65.5M
$702.6M
Q2 25
$22.7M
$364.0M
Q1 25
$14.2M
$596.1M
Q4 24
$79.1M
$742.5M
Q3 24
$96.3M
$703.6M
Q2 24
$33.2M
$658.2M
Q1 24
$1.1M
$664.6M
Free Cash Flow
ALG
ALG
RPRX
RPRX
Q4 25
$69.9M
Q3 25
$53.1M
Q2 25
$15.7M
Q1 25
$8.2M
Q4 24
$73.1M
Q3 24
$88.4M
Q2 24
$28.8M
Q1 24
$-5.5M
FCF Margin
ALG
ALG
RPRX
RPRX
Q4 25
18.7%
Q3 25
12.6%
Q2 25
3.8%
Q1 25
2.1%
Q4 24
19.0%
Q3 24
22.0%
Q2 24
6.9%
Q1 24
-1.3%
Capex Intensity
ALG
ALG
RPRX
RPRX
Q4 25
1.4%
Q3 25
3.0%
Q2 25
1.7%
Q1 25
1.5%
Q4 24
1.6%
Q3 24
2.0%
Q2 24
1.1%
Q1 24
1.6%
Cash Conversion
ALG
ALG
RPRX
RPRX
Q4 25
4.84×
3.86×
Q3 25
2.58×
2.44×
Q2 25
0.73×
12.06×
Q1 25
0.45×
2.50×
Q4 24
2.82×
3.57×
Q3 24
3.51×
1.29×
Q2 24
1.17×
6.45×
Q1 24
0.03×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALG
ALG

Wholegood Units$293.2M78%
Parts$61.6M16%
Other Revenue$18.9M5%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons